Literature DB >> 23984963

Anthrax vaccines: present status and future prospects.

Manpreet Kaur1, Samer Singh, Rakesh Bhatnagar.   

Abstract

The management of anthrax remains a top priority among the biowarfare/bioterror agents. It was the Bacillus anthracis spore attack through the US mail system after the September 11, 2001, terrorist attacks in the USA that highlighted the potential of B. anthracis as a bioterrorism agent and the threat posed by its deliberate dissemination. These attacks invigorated the efforts toward understanding the anthrax pathogenesis and development of more comprehensive medical intervention strategies for its containment in case of both natural disease and manmade, accidental or deliberate infection of a non-suspecting population. Currently, efforts are directed toward the development of safe and efficacious vaccines as well as intervention tools for controlling the disease in the advanced fulminant stage when toxemia has already developed. This work presents an overview of the current understanding of anthrax pathogenesis and recent advances made, particularly after 2001, for the successful management of anthrax and outlines future perspectives.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23984963     DOI: 10.1586/14760584.2013.814860

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  16 in total

Review 1.  Anthrax lethal and edema toxins in anthrax pathogenesis.

Authors:  Shihui Liu; Mahtab Moayeri; Stephen H Leppla
Journal:  Trends Microbiol       Date:  2014-03-27       Impact factor: 17.079

2.  A heterodimer of a VHH (variable domains of camelid heavy chain-only) antibody that inhibits anthrax toxin cell binding linked to a VHH antibody that blocks oligomer formation is highly protective in an anthrax spore challenge model.

Authors:  Mahtab Moayeri; Clinton E Leysath; Jacqueline M Tremblay; Catherine Vrentas; Devorah Crown; Stephen H Leppla; Charles B Shoemaker
Journal:  J Biol Chem       Date:  2015-01-06       Impact factor: 5.157

3.  Generation and Characterization of Human Monoclonal Antibodies Targeting Anthrax Protective Antigen following Vaccination with a Recombinant Protective Antigen Vaccine.

Authors:  Xiangyang Chi; Jianmin Li; Weicen Liu; Xiaolin Wang; Kexin Yin; Ju Liu; Xiaodong Zai; Liangliang Li; Xiaohong Song; Jun Zhang; Xiaopeng Zhang; Ying Yin; Ling Fu; Junjie Xu; Changming Yu; Wei Chen
Journal:  Clin Vaccine Immunol       Date:  2015-03-18

4.  Anthrax Vaccine Precipitated Induces Edema Toxin-Neutralizing, Edema Factor-Specific Antibodies in Human Recipients.

Authors:  Eric K Dumas; Timothy Gross; Jason Larabee; Lance Pate; Hannah Cuthbertson; Sue Charlton; Bassam Hallis; Renata J M Engler; Limone C Collins; Christina E Spooner; Hua Chen; Jimmy Ballard; Judith A James; A Darise Farris
Journal:  Clin Vaccine Immunol       Date:  2017-11-06

5.  Bacteriophage T4 as a Nanoparticle Platform to Display and Deliver Pathogen Antigens: Construction of an Effective Anthrax Vaccine.

Authors:  Pan Tao; Qin Li; Sathish B Shivachandra; Venigalla B Rao
Journal:  Methods Mol Biol       Date:  2017

6.  Production and cell surface display of recombinant anthrax protective antigen on the surface layer of attenuated Bacillus anthracis.

Authors:  Yan-chun Wang; Sheng-ling Yuan; Hao-xia Tao; Ling-chun Wang; Zhao-shan Zhang; Chun-jie Liu
Journal:  World J Microbiol Biotechnol       Date:  2014-12-12       Impact factor: 3.312

Review 7.  Particulate delivery systems for vaccination against bioterrorism agents and emerging infectious pathogens.

Authors:  Yuchen Fan; James J Moon
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2016-04-01

8.  Progress towards the Development of a NEAT Vaccine for Anthrax II: Immunogen Specificity and Alum Effectiveness in an Inhalational Model.

Authors:  Joseph Jelinski; Austen Terwilliger; Sabrina Green; Anthony Maresso
Journal:  Infect Immun       Date:  2020-07-21       Impact factor: 3.441

Review 9.  Bacterial Toxins as Pathogen Weapons Against Phagocytes.

Authors:  Ana do Vale; Didier Cabanes; Sandra Sousa
Journal:  Front Microbiol       Date:  2016-02-01       Impact factor: 5.640

10.  Single-dose combination nanovaccine induces both rapid and durable humoral immunity and toxin neutralizing antibody responses against Bacillus anthracis.

Authors:  Sean M Kelly; Kristina R Larsen; Ross Darling; Andrew C Petersen; Bryan H Bellaire; Michael J Wannemuehler; Balaji Narasimhan
Journal:  Vaccine       Date:  2021-06-02       Impact factor: 4.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.